香蕉直播

As bispecific antibody therapies continue to expand into broader oncology settings, community practices face increasing clinical, operational, and financial complexity. Successfully integrating these therapies requires deliberate planning, coordinated workflows, and a strong focus on patient safety.

Updated playbook edition now available

The new edition of the Bispecific Antibody Therapy Playbook provides practical, high level guidance to help practices safely and effectively integrate bispecific therapies across evolving clinical environments.

Developed by McKesson clinical and business experts, this revised playbook reflects real world experience from practices that have implemented bispecific therapies and incorporates updated clinical, operational, and financial considerations.

The January 2026 edition reflects the evolving bispecific therapy landscape and the growing need for coordinated multidisciplinary delivery models.

Key updates include:

• Enhanced clinical safety and monitoring summaries
  Strengthened guidance on patient monitoring, toxicity recognition, and supportive care workflows that practices can tailor across care settings.
• Clearer operational and implementation framework
  Expanded content focused on cross鈥憈eam communication, hospital coordination, treatment鈥憇etting considerations, caregiver support, and workflow alignment.
• Updated financial, regulatory, and compliance considerations
  Refined insights into reimbursement variability, regulatory requirements, and financial risk considerations based on specialty, payer, and institutional policies.

This edition is designed as a practical, high鈥憀evel reference to help teams assess readiness, identify process gaps, and support cross鈥慸isciplinary planning as bispecific therapies continue to expand into additional areas of care.

What the playbook covers

• Bispecific antibody therapy overview
  Foundational context on therapy types, mechanisms of action, and evolving use across oncology settings.
• Readiness and implementation planning
  Operational considerations related to staffing, workflows, hospital partnerships, and required investments.
• Patient safety, monitoring, and toxicity management
  High level frameworks for monitoring, escalation planning, and coordination of care.
• Operational, financial, and outcomes considerations
  Insights to help practices navigate reimbursement dynamics, documentation needs, and program sustainability.

Who this playbook is for

The Bispecific Antibody Therapy Playbook is designed for:

• Community oncology and hematology practices
• Multidisciplinary care teams involved in bispecific therapy delivery
• Clinical, operational, and financial leaders evaluating or expanding bispecific therapy programs

This resource is intended for educational and planning purposes only and does not constitute medical advice. Practices are encouraged to tailor all guidance based on their clinical workflows, patient populations, and regulatory requirements.